Pancreatic Cancer Research

ResearcherSeoul National UniversityNo recent work listed

Jae Seung Kang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-6587-9579; OpenAlex author ID A5006743757. Sources: OpenAlex.

Their work

Papers
17 (first author 1, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
47
Papers, trials and grants by year

2016: 1 paper · 2017: 1 paper · 2018: 1 paper · 2019: 1 paper · 2020: 2 papers · 2021: 6 papers · 2022: 2 papers · 2023: 3 papers

Papers 17

  1. Impact of conversion surgery on survival in locally advanced pancreatic cancer patients treated with FOLFIRINOX chemotherapy. First author DOI 10.1002/jhbp.1050↗
  2. Role of neoadjuvant treatment in resectable pancreatic cancer according to vessel invasion and increase of CA19-9 levels. Co-author DOI 10.1002/jhbp.1302↗
  3. Multi-biomarker panel prediction model for diagnosis of pancreatic cancer. Co-author DOI 10.1002/jhbp.986↗
  4. Alloferon Affects the Chemosensitivity of Pancreatic Cancer by Regulating the Expression of SLC6A14. Last author DOI 10.3390/biomedicines10051113↗
  5. Oncologic Benefits of Neoadjuvant Treatment versus Upfront Surgery in Borderline Resectable Pancreatic Cancer: A Systematic Review and Meta-Analysis. Co-author DOI 10.3390/cancers14184360↗
  6. Peritumoral lymph nodes in pancreatic cancer revisited; is it truly equivalent to lymph node metastasis? Co-author DOI 10.1002/jhbp.940↗
  7. Diagnostic model for pancreatic cancer using a multi-biomarker panel. Co-author DOI 10.4174/astr.2021.100.3.144↗
  8. CORRIGENDUM: Addition of data source: Diagnostic model for pancreatic cancer using a multi-biomarker panel. Co-author DOI 10.4174/astr.2021.100.4.252↗
  9. Comparison of perioperative short-term outcomes and oncologic long-term outcomes between open and laparoscopic distal pancreatectomy in patients with pancreati… Co-author DOI 10.4174/astr.2021.100.6.320↗
  10. Comparison of Clinical Outcomes of Borderline Resectable Pancreatic Cancer According to the Neoadjuvant Chemo-Regimens: Gemcitabine versus FOLFIRINOX. Co-author DOI 10.5009/gnl20070↗
  11. Development and External Validation of Survival Prediction Model for Pancreatic Cancer Using Two Nationwide Databases: Surveillance, Epidemiology and End Resul… Co-author DOI 10.5009/gnl20306↗
  12. Multi-Biomarker Panel Prediction Model for Diagnosis of Pancreatic Cancer: a retrospective and multi-center cohort study Co-author DOI 10.21203/rs.3.rs-76136/v1↗
  13. The Role of Location of Tumor in the Prognosis of the Pancreatic Cancer. Co-author DOI 10.3390/cancers12082036↗
  14. Role of surgical resection in the era of FOLFIRINOX for advanced pancreatic cancer. Co-author DOI 10.1002/jhbp.648↗
  15. Recent treatment patterns and survival outcomes in pancreatic cancer according to clinical stage based on single-center large-cohort data. Co-author DOI 10.14701/ahbps.2018.22.4.386↗
  16. Clinicopathologic and survival differences in younger patients with pancreatic ductal adenocarcinoma-A propensity score-matched comparative analysis. Co-author DOI 10.1016/j.pan.2017.08.013↗
  17. The anti-fibrotic effect of GV1001 combined with gemcitabine on treatment of pancreatic ductal adenocarcinoma. Last author DOI 10.18632/oncotarget.12057↗

Closest collaborators

The 25 strongest of 47 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jin‐Young Jang · 15 shared papers, 2017–2023 · strength 1.75
  2. Wooil Kwon · 15 shared papers, 2017–2023 · strength 1.75
  3. Hongbeom Kim · 11 shared papers, 2019–2023 · strength 1.25
  4. Yoonhyeong Byun · 10 shared papers, 2019–2023 · strength 1.13
  5. Yoo Jin Choi · 7 shared papers, 2019–2021 · strength 0.78
  6. Mirang Lee · 4 shared papers, 2020–2023 · strength 0.62
  7. Jin Seok Heo · 5 shared papers, 2020–2023 · strength 0.49
  8. Seungyeoun Lee · 5 shared papers, 2020–2023 · strength 0.49
  9. Taesung Park · 5 shared papers, 2020–2023 · strength 0.49
  10. Joo Kyung Park · 5 shared papers, 2016–2023 · strength 0.46
  11. Hyeong Seok Kim · 3 shared papers, 2021–2023 · strength 0.43
  12. Junghyun Namkung · 4 shared papers, 2020–2023 · strength 0.40
  13. Woo Jin Lee · 4 shared papers, 2020–2023 · strength 0.40
  14. Chang Moo Kang · 4 shared papers, 2020–2023 · strength 0.40
  15. Joon Oh Park · 4 shared papers, 2020–2023 · strength 0.40
  16. Song Cheol Kim · 4 shared papers, 2020–2023 · strength 0.40
  17. Do‐Youn Oh · 3 shared papers, 2019–2023 · strength 0.37
  18. Sang Hyub Lee · 3 shared papers, 2019–2023 · strength 0.37
  19. Ji Kon Ryu · 3 shared papers, 2019–2023 · strength 0.37
  20. In Woong Han · 3 shared papers, 2020–2023 · strength 0.29
  21. Huisong Lee · 3 shared papers, 2020–2023 · strength 0.29
  22. Doo‐Ho Lee · 3 shared papers, 2018–2023 · strength 0.29
  23. Eui Kyu Chie · 2 shared papers, 2021–2023 · strength 0.29
  24. Yong‐Tae Kim · 2 shared papers, 2019–2023 · strength 0.26
  25. Sun‐Whe Kim · 3 shared papers, 2017–2019 · strength 0.26

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.